Parkinson’s disease currently affects nearly one million Americans with no specific known cause and no cure. Treatments have ...
Gyre Pharmaceuticals has completed participant enrolment for its 52-week Phase III clinical trial assessing Pirfenidone ...
Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today ...
New research from the George Washington University shows the hidden toll of work injuries caused by workplace exposure to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback